NCT06807502View on ClinicalTrials.gov

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

NARecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

November 30, 2026

Conditions
Breast Cancer, MetastaticBreast Cancer InvasiveBreast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
DEVICE

The DM/DIV ScreenCell is the experimental product studied during this research

The product is not used directly on the subject, but on a blood sample taken from the participant.

Trial Locations (1)

92200

RECRUITING

CMC Ambroise Paré Hartmann, Neuilly-sur-Seine

All Listed Sponsors
collaborator

AXELYS SANTE

UNKNOWN

lead

ScreenCell

INDUSTRY